59279-58-2

Basic information

• Product Name: BOC-GLU(OBZL)-OME
• Synonyms: BOC-GLU(OBZL)-OME;BOC-L-GLUTAMIC ACID GAMMA-BENZYL ESTER ALPHA-METHYL ESTER;BOC-L-GLUTAMIC ACID-GAMMA-BENZYL ALPHA-METHYL-DIESTER;N-ALPHA-T-BUTOXYCARBONYL-L-GLUTAMIC ACID GAMMA-BENZYL ESTER ALPHA-METHYL ESTER;Boc-L-glutamic acid γ-benzyl α-methyl ester;Boc-L-glutamicacid-benzyla-methylester;BOC-L-GLUTAMIC ACID-Y-BENZYL A-METHYL-DIESTER;BOC-L-GLUTAMIC ACID .GAMMA.-BENZYL .ALPHA.-METHYL ESTER
• CAS NO: 59279-58-2
• Molecular Formula: C₁₈H₂₅NO₆
• Molecular Weight: 351.39
• Mol File: 59279-58-2.mol

Chemical Properties

• Appearance: /
• Storage Temp.: Store at 0°C
• CAS DataBase Reference: BOC-GLU(OBZL)-OME(CAS DataBase Reference)
• NIST Chemistry Reference: BOC-GLU(OBZL)-OME(59279-58-2)
• EPA Substance Registry System: BOC-GLU(OBZL)-OME(59279-58-2)

Safety Data

• Hazardous Substances Data: 59279-58-2(Hazardous Substances Data)

Usage

Uses

Used in Organic Chemistry:
BOC-GLU(OBZL)-OME is used as a reagent in the synthesis of peptides, where its protecting groups play a crucial role in controlling the reactivity of the molecule during the assembly process.
Used in Pharmaceutical Industry:
BOC-GLU(OBZL)-OME is used as a building block for the development of new pharmaceutical compounds, particularly in the synthesis of complex peptide-based drugs. Its protecting groups ensure that the molecule can be selectively modified and assembled into the desired drug structure without interference from other reactive sites.
Used in Research and Development:
BOC-GLU(OBZL)-OME is employed as a research tool in academic and industrial laboratories, where it is used to study the synthesis and properties of peptides and other biomolecules. Its unique structure and protecting groups make it an interesting subject for exploration in the field of organic chemistry and biochemistry.

Upstream product

• 13574-13-5 Boc-Glu(OBzl)-OH 
• 77-78-1 dimethyl sulfate 
• 100-51-6 benzyl alcohol 
• 1676-73-9 L-glutamic acid γ-benzyl ester 
• 56-86-0 L-glutamic acid 
• 74-88-4 methyl iodide 
• 67-56-1 methanol 
• 104706-58-3 Boc-Glu(OBzl)-OBt 
• 18107-18-1 diazomethyl-trimethyl-silane 
• 186581-53-3 diazomethane 

Downstream Products

• 188200-08-0 (3R,6S,8aS)-5-Oxo-6-phenylmethanesulfonylamino-hexahydro-thiazolo[3,2-a]pyridine-3-carboxylic acid 
• 206268-50-0 (R)-4-Benzyloxycarbonylamino-2-tert-butoxycarbonylamino-butyric acid methyl ester 
• 216309-95-4 -L-glutamic acid 1-methyl 5-benzyl diester 
• 1053423-71-4 -L-glutamic acid 1-methyl 5-benzyl diester 
• 216309-89-6 N-(tert-butoxycarbonyl)-D-seryl-L-glutamic acid 1-methyl 5-benzyl diester 
• 89985-87-5 methyl (2S)-2-tert-butoxycarbonylamino-4-pentenoate 
• 144051-35-4 Boc-γ-Glu(OMe)-Glu(OBzl)-OMe 

Relevant articles and documents

An irreversible inhibitor of peptidyl-prolyl cis/trans isomerase Pin1 and evaluation of cytotoxicity

Pin1 (protein interacting with never in mitosis A-1) is a member of the peptidyl prolyl isomerase (PPIase) family, and catalyzes cis-trans isomerization of pThr/Ser-Pro amide bonds. Because Pin1 is overexpressed in various cancer cell lines and promotes c

Visible-Light Photoredox Synthesis of Chiral α-Selenoamino Acids

N-Acetoxyphthalimide derivatives of two genetically coded proteinogenic amino acids, l-aspartic acid and glutamic acid, were used as visible light photoredox chiral sources and radical precursors, diorganyl diselenides were used as the radical acceptors,

Synthesis of l -Kynurenine and Homo- l -Kynurenine via an Aza-Fries Rearrangement

l -Kynurenine, a non-proteinogenic amino acid, is the primary metabolite of tryptophan via the kynurenine pathway. Kynurenine is involved in a variety of biological processes occurring in the human body, notably in the central nervous system. Thus, the st

Dearomatization of 3-Nitroindoles with Highly γ-Functionalized Allenoates in Formal (3+2) Cycloadditions

3-Nitroindoles are easily reacted with highly substituted γ-allenoates in the presence of a commercially available phosphine catalyst. For instance, allenoates derived from biomolecules such as amino and deoxycholic acids are combined for the first time w

Oxadiazole-Based Cell Permeable Macrocyclic Transition State Inhibitors of Norovirus 3CL Protease

Human noroviruses are the primary causative agents of acute gastroenteritis and a pressing public health burden worldwide. There are currently no vaccines or small molecule therapeutics available for the treatment or prophylaxis of norovirus infections. Norovirus 3CL protease plays a vital role in viral replication by generating structural and nonstructural proteins via the cleavage of the viral polyprotein. Thus, molecules that inhibit the viral protease may have potential therapeutic value. We describe herein the structure-based design, synthesis, and in vitro and cell-based evaluation of the first class of oxadiazole-based, permeable macrocyclic inhibitors of norovirus 3CL protease.

Synthesis of rhodotorulic acid and its 1,4-dimethylated derivative

Facile syntheses of rhodotorulic acid, isolated from Rhodotorula pilimanae as a siderophore, and its 1,4-dimethylated derivative have been achieved by microwave-assisted cyclization of the corresponding dipeptide precursors.

Synthesis of triazole cages containing C3-symmetric α-cyclic tripeptide scaffold

Two water-soluble C3-symmetric 1,2,3-triazole cages containing α-cyclic tripeptide were efficiently synthesized. The key steps include a click reaction to incorporate l-glutamic or l-aspartic acids to a tripodal linker and a unique one-pot cyclotrimerization.

BORON CONTAINING POLYBASIC BACTERIAL EFFLUX PUMP INHIBITORS AND THERAPEUTICS USES THEREOF

Disclosed herein are polybasic bacterial efflux pump inhibitors containing boronic acid functionality and theft methods of synthesis, methods of use, and pharmaceutical compositions. Some embodiments include methods of treating or preventing a bacterial infection by co-administering to a subject infected with bacteria or at risk of infection with bacteria the efflux pump inhibitor with another anti-bacterial agent

PYRIDINE DERIVATIVES SUBSTITUTED WITH HETEROCYCLIC RING AND gamma-GLUTAMYLAMINO GROUP, AND ANTIFUNGAL AGENTS CONTAINING SAME

The present invention provides an antifungal agent which has excellent antifungal action, and which is also excellent in terms of its properties, and in particular its solubility in water and safety. The present invention discloses a compound represented

POLYBASIC BACTERIAL EFFLUX PUMP INHIBITORS AND THERAPEUTIC USES THEREOF

Disclosed are compounds having polybasic functionalities. The compounds inhibit bacterial efflux pump inhibitors and are used in combination with an anti-bacterial agent to treat or prevent bacterial infections. These combinations can be effective against bacterial infections that have developed resistance to anti-bacterial agents through an efflux pump mechanism.